Prostate Cancer
Prostate Cancer Treatment: What to Know About Active Surveillance
00
Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices Prostate cancer (PC) is the second most common cancer
Prostate Cancer
Hormone Therapy for Prostate Cancer
00
A Framework for Treatment Decision Making at Prostate Cancer Recurrence 1. National Cancer Institute Surveillance Research Program. 8.3.
Prostate Cancer
Systemic Therapy for Prostate Cancer
00
SABR prolongs survival in men with oligometastatic PCa Stereotactic body radiation (SABR) reduced the lihood for future PSA rises and significantly prolonged
Prostate Cancer
Radiation Therapy for Prostate Cancer
00
Highly Focused Radiation may Slow Down Progression in Men with Prostate Cancer A highly focused, intense doses of radiation called stereotactic ablative
Prostate Cancer
Prostatectomy: What to Expect During Surgery and Recovery
00
Cigarette Smoking and Prostate Cancer Recurrence After Prostatectomy Few studies have examined the influence of cigarette smoking on risk of prostate cancer recurrence.
Prostate Cancer
Prostate Cancer: Age-Specific Screening Guidelines
00
Prostate Cancer Tests as Routine Not Recommended for All Men Boana | E+ | Getty Images Top doctors are calling attention to new guidance on screening for
Prostate Cancer
Prostate Cancer Treatment: What to Know About Active Surveillance
00
Active Surveillance in Prostate Cancer Transcript: Raoul S. Concepcion, MD, FACS: Historically, using traditional ultrasound-guided 12-core biopsy, we
Prostate Cancer
Prostate Cancer Statistics
00
Johns Hopkins Gazette | November 5, 2007 A popular prostate cancer treatment called androgen deprivation therapy, which suppresses testosterone, may encourage
Prostate Cancer
Prostate Cancer Screening: 4 Questions Answered
00
Prostate Cancer Nomograms Our prostate cancer nomograms are prediction tools designed to help patients and their physicians understand the nature of their
Prostate Cancer
Prostate Cancer Risk Factors
00
Johns Hopkins Gazette | August 8, 2005 Researchers at Johns Hopkins and its Brady Urological Institute have identified three risk factors and developed